MSDC-0160
MSDC-0160 (CAS 146062-49-9) is a thiazolidinedione insulin sensitizer that acts independently of peroxisome proliferator-activated receptor gamma (PPAR-γ). By modulating mitochondrial targets associated with nutrient sensing, MSDC-0160 enhances insulin sensitivity, inhibits mTOR phosphorylation, and increases AMPK phosphorylation. In human pancreatic islets, MSDC-0160 preserves insulin content, reduces apoptotic markers such as cleaved caspase-3, increases expression of pro-survival genes including BCL2, and prevents nuclear translocation of β-catenin. MSDC-0160 is thus relevant for studies on metabolic signaling, β-cell preservation, and diabetes research.
| Storage | Store at -20°C |
| M.Wt | 370.42 |
| Cas No. | 146062-49-9 |
| Formula | C19 H18 N2 O4 S |
| Solubility | ≥37 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| SDF | Download SDF |
| Canonical SMILES | CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
LUHMES cells |
|
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
10 or 100 μM, 1 hour |
|
Applications |
MSDC-0160 (10 μM) pretreatment (1 hour) prevented the MPP+ (10 μM)-induced loss of both tyrosine hydroxylase (TH)-immunoreactive differentiated Lund human mesencephalic (LUHMES) cells. MSDC-0160 protected TH-immunoreactive neurons. MSDC-0160 counteracted both MPP+-induced shortening of neurite length and reduced branching in both LUHMES cells. MSDC-0160 (10 or 100 μM) prevented the loss of GFP-fluorescent dopaminergic neurons induced by MPP+ (0.75 mM) in nematodes. MSDC-0160 (10 μM) blocked LPS-induced increases in iNOS expression in BV2 cell lysates. |
| Animal experiment [1]: | |
|
Animal models |
MPTP mouse model of Parkinson’s disease (PD), En1+/- genetic mouse model of PD |
|
Dosage form |
Oral administration, 30 mg/kg per day |
|
Application |
MSDC-0160 (30 mg/kg per day, p.o.) treatment for 3 days after MPTP injection improved motor behavior, protects nigrostriatal neurons, and suppressed disease progression in the MPTP mouse model of Parkinson’s disease (PD). MSDC-0160 improved motor behavior in the open-field and rotarod tests and prevented dopaminergic neurodegeneration in the En1+/- genetic mouse model of PD. MSDC-0160 modulated mTOR signaling in C. elegans and the MPTP mouse model of PD. MSDC-0160 down-regulated mTOR signaling and restored autophagy in the En1+/- genetic mouse model of PD. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Rohatgi N, Aly H, Marshall C A, et al. Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. PloS one, 2013, 8(5): e62012. |
|
| Description | MSDC-0160 is a novel modulator of mTOT. | |||||
| Targets | mTOT | |||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
